saphnelo
(Anifrolumab-fnia)AstraZeneca Pharmaceuticals LP
Usage: SAPHNELO (anifrolumab-fnia) is indicated for treating adult patients with moderate to severe systemic lupus erythematosus (SLE) who are undergoing standard therapy. It is not recommended for patients with severe active lupus nephritis or severe central nervous system lupus due to lack of efficacy data.